ClinicalTrials.gg
CompletedNCT03676322Updated Dec 3, 2019

Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants

A Phase 1 interventional study of M5049 and Placebo in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-03.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study will evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamics (PD), and explore the food effect of M5049 in healthy male and female participants.

02

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetics
  • M5049
03

In context

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight between 50 to 100 kilogram (kg)
  • (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m\^2)
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • History of disease of any organ system that may interfere with the objectives of the study or provide a risk to the health of the participant
  • History of splenectomy
  • History of epilepsy, other neurological disorders, or neuropsychiatric conditions
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Part A: M5049

    Drug: M5049

  • Placebo comparator
    Part A: Placebo

    Drug: Placebo

  • Experimental
    Part B: M5049

    Drug: M5049

  • Placebo comparator
    Part B: Placebo

    Drug: Placebo

  • Experimental
    Part C: M5049

    Drug: M5049

Interventions

  • DrugM5049

    Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.

  • DrugPlacebo

    Participants will receive placebo matched to M5049.

06

What researchers measure

Primary outcomes

  1. Part A: Occurrence and Severity of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs)

    Time frame: Day 1 up to Day 21

  2. Part A: Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings

    Number of participants with clinically significant changes will be reported.

    Time frame: Day 1 up to Day 21

  3. Part B: Occurrence and Severity of TEAEs and SAEs

    Time frame: Day 1 up to Day 33

  4. Part B: Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings

    Number of participants with clinically significant changes will be reported.

    Time frame: Day 1 up to Day 33

  5. Part C: Maximum Observed Plasma Concentration (Cmax) of M5049

    Time frame: Pre-dose up to Day 6

  6. Part C: Time to Reach Maximum Plasma Concentration (tmax) of M5049

    Time frame: Pre-dose up to Day 6

  7. Part C: Elimination Rate Constant (λz) of M5049

    Time frame: Pre-dose up to Day 6

  8. Part C: Apparent Terminal Half-life (t1/2) of M5049

    Time frame: Pre-dose up to Day 6

  9. Part C: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of M5049

    Time frame: Pre-dose up to Day 6

  10. Part C: Area Under the Concentration-Time Curve Over Entire Dosing Time Period From Time Zero Extrapolated to Infinity (AUC0-inf)

    Time frame: Pre-dose up to Day 6

  11. Part C: Total Body Clearance (CL/f) of M5049

    Time frame: Pre-dose up to Day 6

  12. Part C: Apparent Volume of Distribution (Vz/f) of M5049

    Time frame: Pre-dose up to Day 6

Secondary outcomes

  1. Part A: Maximum Observed Blood Concentration (Cmax) of M5049

    Time frame: Pre-dose up to Day 6

  2. Part A: Time to Reach Maximum Plasma Concentration (tmax) of M5049

    Time frame: Pre-dose up to Day 6

  3. Part A: Elimination Rate Constant (λz) of M5049

    Time frame: Pre-dose up to Day 6

  4. Part A: Apparent Terminal Half-life (t1/2) of M5049

    Time frame: Pre-dose up to Day 6

  5. Part A: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of M5049

    Time frame: Pre-dose up to Day 6

  6. Part A: Area Under the Concentration-Time Curve Over Entire Dosing Time Period From Time Zero Extrapolated to Infinity (AUC0-inf)

    Time frame: Pre-dose up to Day 6

  7. Part A: Total Body Clearance (CL/f) of M5049

    Time frame: Pre-dose up to Day 6

  8. Part A: Apparent Volume of Distribution (Vz/f) of M5049

    Time frame: Pre-dose up to Day 6

  9. Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax/D) of M5049

    Time frame: Pre-dose up to Day 6

  10. Part A: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t/D) of M5049

    Time frame: Pre-dose up to Day 6

  11. Part A: Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) on Digital Holter Electrocardiograms (ECG) at Day 2

    Time frame: Baseline, Day 2

  12. Part A: Time Matched Plasma Concentration of M5049

    Time frame: Pre-dose up to Day 6

  13. Part B: Maximum Observed Blood Concentration (Cmax) of M5049

    Time frame: Pre-dose up to Day 19

  14. Part B: Time to Reach Maximum Plasma Concentration (tmax) of M5049

    Time frame: Pre-dose up to Day 19

  15. Part B: Elimination Rate Constant (λz) of M5049

    Time frame: Pre-dose up to Day 19

  16. Part B: Apparent Terminal Half-life (t1/2) of M5049

    Time frame: Pre-dose up to Day 19

  17. Part B: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of M5049

    Time frame: Pre-dose up to Day 19

  18. Part B: Area Under the Concentration-Time Curve Over Entire Dosing Time Period From Time Zero Extrapolated to Infinity (AUC0-inf)

    Time frame: Pre-dose up to Day 19

  19. Part B: Total Body Clearance (CL/f) of M5049

    Time frame: Pre-dose up to Day 19

  20. Part B: Apparent Volume of Distribution (Vz/f) of M5049

    Time frame: Pre-dose up to Day 19

  21. Part B: Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau)

    Time frame: Pre-dose up to Day 19

  22. Part B: Accumulation Ratio for Cmax (Racc Cmax) of M5049

    Time frame: Pre-dose up to Day 19

  23. Part B: Accumulation Ratio for AUCtau(Racc AUCtau) of M5049

    Time frame: Pre-dose up to Day 19

  24. Part B: Peak trough Ratio of M5049

    Time frame: Pre-dose up to Day 19

  25. Part B: Plasma Concentration Prior to the Next Dose (C trough) of M5049

    Time frame: Pre-dose up to Day 19

  26. Part B: Dose Normalized Maximum Observed Plasma Concentration at Steady State (Cmaxss/D) of M5049

    Time frame: Pre-dose up to Day 19

  27. Part B: Dose Normalized Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau/D) of M5049

    Time frame: Pre-dose up to Day 19

  28. Part B: Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) on Digital Holter Electrocardiograms (ECG) at Day 2

    Time frame: Baseline, Day 2

  29. Part B: Time Matched Plasma Concentration of M5049

    Time frame: Pre-dose up to Day 19

  30. Part C: Occurrence and Severity of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs)

    Time frame: Day 1 up to Day 23

  31. Part C: Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings

    Number of participants with clinically significant changes will be reported.

    Time frame: Day 1 up to Day 23

07

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, 89231, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Jul 2019, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2018
First posted
Sep 18, 2018
StartActual
Sep 20, 2018
Primary completionActual
Jul 26, 2019
CompletionActual
Jul 26, 2019
Last update
Dec 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03676322
Responsible party
Sponsor
First posted
Sep 18, 2018
Start date
Sep 20, 2018
Primary completion
Jul 26, 2019
Completion
Jul 26, 2019
Last update
Dec 3, 2019

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enpatoran

Start the discussion